Osaka, Japan

Tadahiko Yoshima

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2002-2017

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Tadahiko Yoshima

Introduction

Tadahiko Yoshima is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 4 patents to his name, Yoshima's work has the potential to impact the treatment of various inflammatory diseases.

Latest Patents

Yoshima's latest patents focus on human monoclonal antibodies. One of his inventions provides a method for the prophylaxis, improvement, or treatment of inflammatory bowel disease, multiple sclerosis, and psoriasis. This is achieved by administering an effective amount of an isolated anti-human CD81 antibody capable of binding to a specific peptide region. Another patent presents an anti-CD81 antibody that can be utilized as a pharmaceutical product for humans, specifically targeting the same peptide region.

Career Highlights

Throughout his career, Yoshima has worked with notable companies in the pharmaceutical industry, including Sumitomo Dainippon Pharma Co., Ltd. and Dainippon Sumitomo Pharma Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative medical solutions.

Collaborations

Yoshima has collaborated with several professionals in his field, including Takamasa Watanabe and Mikael Mattsson. These partnerships have likely enhanced his research and development efforts, leading to his successful patent applications.

Conclusion

Tadahiko Yoshima's contributions to the field of biotechnology through his patents on human monoclonal antibodies demonstrate his commitment to advancing medical science. His work has the potential to improve the lives of many individuals suffering from inflammatory diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…